KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Finished Goods (2017 - 2025)

Bionano Genomics' Finished Goods history spans 7 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Finished Goods fell 78.53% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, down 78.53%, while the annual FY2024 figure was $4.2 million, 58.89% down from the prior year.
  • Finished Goods for Q3 2025 was $2.0 million at Bionano Genomics, down from $3.3 million in the prior quarter.
  • Across five years, Finished Goods topped out at $19.8 million in Q2 2022 and bottomed at $300000.0 in Q1 2021.
  • The 5-year median for Finished Goods is $9.1 million (2024), against an average of $9.6 million.
  • The largest annual shift saw Finished Goods tumbled 79.63% in 2021 before it soared 4943.0% in 2022.
  • A 5-year view of Finished Goods shows it stood at $6.1 million in 2021, then surged by 186.06% to $17.4 million in 2022, then tumbled by 41.08% to $10.2 million in 2023, then plummeted by 58.89% to $4.2 million in 2024, then plummeted by 53.63% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Finished Goods are $2.0 million (Q3 2025), $3.3 million (Q2 2025), and $3.3 million (Q1 2025).